Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CRT-D · 1 trial · 5 indications
| Name | Type | Description |
|---|---|---|
| CRT-D | DEVICE | - |
Inclusion Criteria: * Indications for the device * Availability for follow-up at an approved Field Following center, at the protocol defined intervals * Willing and capable of undergoing a device implant and participating in all testing associated with this clinical investigation * Prescribed to st...
Top 20 of 31 competitors
CRT-D is a cardiac resynchronization therapy defibrillator used for heart failure. It is being studied for conditions including heart failure, tachycardia, atrial fibrillation, atrial flutter, and ventricular fibrillation. The device is intended to coordinate heart contractions and deliver defibrillation when needed.
CRT-D is developed by Boston Scientific Corporation, a company traded on the New York Stock Exchange under the ticker BSX. Boston Scientific is the sponsor of the clinical trial evaluating this device for heart failure and related cardiac arrhythmias.
CRT-D is in Phase 2 clinical development. A Phase 2 study has been completed, and the device remains investigational for the treatment of heart failure and associated arrhythmias. It is not yet approved for commercial use.
CRT-D has one completed clinical trial, NCT00180336, titled 'Safety and Efficacy Study of RENEWAL 4 AVT.' This Phase 2 study enrolled 170 participants in Germany and evaluated the device in patients with heart failure, tachycardia, atrial fibrillation, atrial flutter, and ventricular fibrillation.
CRT-D is associated with the RENEWAL 4 AVT device, as indicated by the clinical trial title 'Safety and Efficacy Study of RENEWAL 4 AVT.' The trial evaluates CRT-D, and RENEWAL 4 AVT appears to be the specific model or system name for this cardiac resynchronization therapy defibrillator.